Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies for cancer and eye diseases. The Company focuses on developing activities that covers targets, including vascular endothelial growth factors (VEGF-C, VEGF-D and VEGF receptor-3). It develops therapies for the treatment of diseases associated with blood and lymphatic vessel growth, such as angiogenesis, lymphangiogenesis and vascular leakage.
Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.
Asian Activities Report for October 31, 2011 includes: Endocoal Limited (ASX:EOC) announces a 505% increase in JORC Resource at Rockwood coal project in Queensland; Circadian Technologies Limited (ASX:CIR) has received approval from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100 in the USA; Golden Gate Petroleum Ltd (ASX:GGP) says today that the SRH-A #8A well in the Permian Basin Project in the USA has reached a total depth of 9,500 feet; Cove Resources Limited (ASX:CVE) has entered into a binding agreement for the acquisition of 100% of Blenheim Resources Limited.
Asian Activities Report for September 30, 2011 includes: Neon Energy Limited (ASX:NEN) says today that the recently drilled Lombardi 19-27H development well in the North San Ardo oil field, onshore California, has been brought onstream; India Resources Limited (ASX:IRL) has signed a A$249M coal operations contract with Prism Cement Limited (BOM:500338) to develop and operate the first phase of Prism's Sial Ghoghri coal mine; Guildford Coal Limited (ASX:GUF) has upgraded its Exploration Targets at its Mongolian coal projects to 30Mt to 1.380Bt; Tissue Therapies Limited (ASX:TIS) will start the sales of VitroGro(R) for the treatment of chronic wounds in the UK and Europe during the second quarter of 2012; Biotron Limited (ASX:BIT) has commenced a human trial of its lead HIV drug candidate, BIT225; Circadian Technologies Limited (ASX:CIR) has submitted an investigational new drug application to the FDA to initiate clinical studies of VGX-100.
Asian Activities Report for April 6, 2011 includes: Motopia Limited's (ASX:MOT) subsidiary cBox Pty Ltd has been appointed as Business Wire's Australasian media distribution partner; MACA Limited (ASX:MLD) is to provide iron ore crushing and screening services for WPG Resources Limited (ASX:WPG); Rey Resources Limited (ASX:REY) announced an upgraded thermal coal Measured Resources at Duchess Paradise Project; Circadian Technologies Limited (ASX:CIR) said that VGX-100 significantly inhibits the growth and spread of various types of human tumour.
